Our Vision and Mission
Precision Medicine offers a groundbreaking approach to tackling currently incurable diseases by focusing on early detection, targeting causative genetics, safe delivery to affected cells, and durable efficacy for cures. Utilizing cutting-edge tools like biomarkers, RNAi, CRISPR, and targeted drug delivery systems, Precision Medicine stands at the forefront of medical innovation.
EGE (Epigenetic Gene Editing) aspires to lead the market as a first-in-class, best-in-class provider, aiming for a dominant market position akin to industry giants such as Abbvie with Humira. With a focus on sustained market presence and multiple applications over a 10-15 year patent lifespan post-FDA approval, EGE seeks to revolutionize autoimmune disease treatment and establish a lasting legacy in Precision Medicine innovation.
-
Reem Mahrat
CEO
Reem Maharat is an accomplished leader in the biopharmaceutical industry, known for her visionary roles and pioneering initiatives. With a career spanning over two decades, Reem has been at the forefront of transformative healthcare innovations and a steadfast advocate for precision medicine.
Reem's influence extends to her Advisor role at Daybreak Labs and the founder and CEO of RamanID, Calico Biolabs, Inc., Verano Bioscience, and Precision Biopharma. In these diverse positions, she has consistently demonstrated exceptional leadership and expertise, driving progress in both scientific and technological domains.
As a passionate advocate for precision medicine, Reem actively promotes advancements in healthcare through her involvement with the American Association for Precision Medicine. She envisions a future where personalized healthcare and compassion intersect to revolutionize healthcare solutions while also advocating for women's empowerment in the industry.
Reem Maharat's commitment to innovation is further exemplified by her role as the CEO of EGE, a gene editing platform focused on discovering cures for autoimmune diseases. Drawing from her extensive experience and personal journey as someone living with an autoimmune disease, Reem channels her passion for precision medicine into steering EGE towards groundbreaking advancements in gene editing technology.
-
Lonnie Bookbinder, MBA, Ph.D
CHAIRMAN
Lonnie Bookbinder, MBA, PhD., is a serial entrepreneur with a strong emphasis on precision medicine drug development. His experience in working for bio-pharmaceutical companies and his educational experience in pharmacology and toxicology have led him to utilize drug delivery systems to target diseases with potentially curative outcomes in cancer, autoimmune infectious diseases as well as metabolic syndromes such as obesity & diabetes.
Lonnie serves as Chairman of the Board of four companies he founded and funded. He’s held financial, sales & marketing, clinical research, and corporate development positions, including COO & CEO responsibilities. His ability to identify product opportunities based on the root cause of diseases & forecast markets is an area of expertise he conveys to CEOs he trained. He’s created patents and wrote books on disease causation, diagnosis & therapy.
-
Bill Howell, M.D., Ph.D
CMO
William D. Howell, M.D., Ph.D. is a physician-scientist who trained in anatomic, clinical, and molecular genetic pathology at Stanford University and internal medicine at the University of Utah. He “knocked out” a gene essential for mouse gastrulation and described the phenotype for his Ph.D. work in Mario Capecchi’s lab. Following completion of his clinical training, he provided pathology services tailored to pharmaceutical development for several CROs contracting with Abbvie, Roche/Genentech, Gilead, Armo, Medimmune, Cytomx, Tesaro, BD, Pharmacyclics, Stemcentrx, Avast, Curis, Peloton, Pulse Biosciences, Halozyme, and Atreca. He was one of four pathologists contributing to a 510K submission of an early computer-aided breast cancer immunohistochemical marker quantitation system for Roche/Ventana/BioImagene.
During the COVID-19 pandemic, he was the CMO of a startup repurposing a drug with unique immunomodulatory and antiviral mechanisms of action for the treatment of acute and long-term COVID-19. He worked for the diagnostic startup, RamanID, as CMO achieved a successful exit in 2024.